5 products found
Alkermes Products
-
United States - US Products Using Alkermes Technologies
All product information provided on this page is intended for the U.S. audience only. The products listed below may not be available in countries outside the U.S. or may be available under a different trademark name; in different strengths; or for different indications. Countries outside the U.S. may have different regulatory requirements that would call for different information to be made available with respect to these products.
-
Aristada - Aristada - Aripiprazole Lauroxi
ARISTADA® (aripiprazole lauroxil) extended-release injectable suspension is a long-acting atypical antipsychotic that is approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults. ARISTADA is available in four dose strengths with once-monthly dosing (441 mg, 662 mg, 882 mg), a six-week dosing option (882 mg) and a two-month dosing option (1064 ...
-
Vivitrol - Naltrexone for Extended-Release Injectable Suspension
VIVITROL (naltrexone for extended-release injectable suspension) is a once-monthly medication for the treatment of alcohol dependence as well as for the prevention of relapse to opioid dependence, following opioid detoxification. Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial ...
-
European Union - EU Products Using Alkermes Technologies
All product information provided is intended for the European Union audience only. These products may not be available in all Member States of the EU, or in countries outside the EU or may be available under a different trademark; in different strengths; or for different indications. Countries outside the EU may have different regulatory requirements that would call for different information to be available.
-
Bydureon - Model 2mg - Bydureon - Powder and Solvent injection
Bydureon 2mg powder and solvent for prolonged-release suspension for ...
-
Fampyra - Model 10 mg - Prolonged Release Tablets
Fampyra 10 mg prolonged-release tablets. The recommended dose is one 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening). Fampyra should not be administered more frequently or at higher doses than recommended (see section 4.4). The ...
-
Risperdal Consta - Benzisoxazole Derivative Tablets
Risperdal Consta (risperidone) is a benzisoxazole derivative with potent combined serotonin 5HT2A and dopamine D2 receptor-blocking properties. It is an effective atypical antipsychotic that is well tolerated, based on extensive clinical experience including long-term use. The authorised formulation of Risperdal Consta is a prolonged-release ...